Hyderabad ki startup PopVax ne Australia mein apne naye COVID-19 vaccine, PVX-001, ke liye Phase 1 trials shuru kar diye hain. Ye vaccine normal fridge mein 9 mahine tak stable reh sakti hai. Yaad rahe, ye ek private startup hai aur stock market par listed nahi hai.
Trial ka kya status hai?
Hyderabad ki biotech startup PopVax ne apne lead vaccine candidate, PVX-001, ke saath ek bada step liya hai. Abhi Melbourne, Australia mein Phase 1 clinical trials chal rahe hain. October 2026 tak, 36 mein se 14 adults ko dose di ja chuki hai aur abhi tak koi serious safety issue samne nahi aaya hai.
Kya hai iski khaas baat?
Innovation ki baat karein toh, purane mRNA vaccines ko bahut low temperature par rakhna padta tha, jisse distribution mein dikkat aati thi. Lekin PopVax ki vaccine normal fridge temperature yani 2-8°C par 9 mahine tak survive kar sakti hai. Ye remote aur rural areas mein vaccine pohchane ke liye game-changer ho sakta hai.
Investors ke liye zaroori note
Market mein active traders dhyan dein: PopVax filhal ek private company hai. Ye NSE ya BSE par listed nahi hai, isliye iska koi share price track karne ki zaroorat nahi hai. Haan, ye news Indian biotech sector ki growth ko samajhne ke liye zaroor important hai.
Funding aur future plans
Company ko $13.5 million se zyada ki funding mil chuki hai. Isme Bill & Melinda Gates Foundation, NIAID, Balvi (Vitalik Buterin supported), aur Good Ventures jaise bade naam shamil hain. Inka plan open-source design ka hai, taki dusre countries bhi isse local level par bana sakein. Phase 1 abhi safety aur dosage par focus kar raha hai, aage chal kar Phase 2 aur 3 ka safar abhi baaki hai.